{"id":4638,"date":"2016-10-10T08:12:09","date_gmt":"2016-10-10T12:12:09","guid":{"rendered":"https:\/\/medicarereport.org\/?p=4638"},"modified":"2016-10-10T08:12:09","modified_gmt":"2016-10-10T12:12:09","slug":"the-race-to-create-a-new-class-of-ovarian-cancer-drugs-heats-up","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=4638","title":{"rendered":"The race to create a new class of ovarian cancer drugs heats up"},"content":{"rendered":"<p>(By Meghana Keshavan for ST<em>A<\/em>T)<\/p>\n<p><br class=\"Apple-interchange-newline\" \/>The race to create the next potent\u00a0ovarian cancer drug is coming to a head.<\/p>\n<p class=\"danger-zone\">Ovarian cancer has historically been one of the harder cancers to treat \u2014 but a promising new class of drugs, called PARP inhibitors, is proving powerful in delaying the growth of tumors by preventing cancer cells from repairing themselves after they\u2019ve been damaged by chemotherapy. <a href=\"https:\/\/www.statnews.com\/2016\/10\/08\/ovarian-cancer-drug-parp\/\" target=\"_blank\">Continue reading article here&#8230;&#8230;..<\/a><\/p>\n<p class=\"danger-zone\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"stat-logo\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre style=\"border: 1px solid #eaeaea; font-variant-ligatures: normal; font-variant-caps: normal; font-variant-numeric: inherit; font-stretch: inherit; line-height: 1.4; font-family: 'Courier 10 Pitch', Courier, monospace; font-size: 14px; font-style: normal; font-weight: normal; margin: 0px 0px 20px; outline: 0px; padding: 20px; vertical-align: baseline; background-color: #ffffff; overflow: auto; white-space: pre-wrap; color: #444444; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px;\"><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Meghana Keshavan for STAT) The race to create the next potent\u00a0ovarian cancer drug is coming to a head. Ovarian<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,15],"tags":[],"class_list":["post-4638","post","type-post","status-publish","format-standard","hentry","category-health-care-general","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4638"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4638\/revisions"}],"predecessor-version":[{"id":4640,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4638\/revisions\/4640"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}